Compare · OMCL vs XNDU
OMCL vs XNDU
Side-by-side comparison of Omnicell Inc. (OMCL) and Xanadu Quantum Technologies Limited (XNDU): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OMCL and XNDU operate in Computer Manufacturing (Technology), so they compete in similar markets.
- OMCL is the larger of the two at $1.53B, about 2.7x XNDU ($566.5M).
- OMCL has been more active in the news (9 items in the past 4 weeks vs 7 for XNDU).
- OMCL has more recent analyst coverage (24 ratings vs 5 for XNDU).
- Company
- Omnicell Inc.
- Xanadu Quantum Technologies Limited
- Price
- -
- -
- Market cap
- $1.53B
- $566.5M
- 1M return
- -8.60%
- -
- 1Y return
- -3.34%
- -
- Industry
- Computer Manufacturing
- Computer Manufacturing
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2001
- News (4w)
- 9
- 7
- Recent ratings
- 24
- 5
Omnicell Inc.
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. In addition, the company provides automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; single dose automation solutions to fill and label for incoming prescriptions; semi-automated filling equipment for the long-term care institutional pharmacy; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
Latest OMCL
- EVP & Chief Financial Officer Harlan Baird Radford covered exercise/tax liability with 4,443 shares, decreasing direct ownership by 6% to 65,526 units (SEC Form 4)
- EVP&CHIEF LEGAL/ADMIN OFFICER Corey J Manley covered exercise/tax liability with 4,025 shares, decreasing direct ownership by 4% to 104,960 units (SEC Form 4)
- President & COO Nnamdi Njoku covered exercise/tax liability with 3,670 shares and sold $107,905 worth of shares (3,083 units at $35.00) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 154,471 units (SEC Form 4)
- VP, Chief Accounting Officer Brian H. Nutt covered exercise/tax liability with 406 shares, decreasing direct ownership by 2% to 21,860 units (SEC Form 4)
- CHAIRMAN, CEO Randall A Lipps covered exercise/tax liability with 12,349 shares, decreasing direct ownership by 2% to 498,747 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Omnicell Inc.
- SEC Form 10-Q filed by Omnicell Inc.
- SEC Form 8-K filed by Omnicell Inc.
- Omnicell Announces Third Quarter 2026 Financial Results
- Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026
Latest XNDU
- Amendment: SEC Form SCHEDULE 13G/A filed by Xanadu Quantum Technologies Limited
- SEC Form 424B3 filed by Xanadu Quantum Technologies Limited
- SEC Form 424B3 filed by Xanadu Quantum Technologies Limited
- SEC Form 6-K filed by Xanadu Quantum Technologies Limited
- Xanadu Announces Third Quarter 2026 Results
- Xanadu and HyperLight Achieve Breakthrough of Nearly 3x Reduction in Optical Switch Loss, Accelerating Path to Commercial Photonic Quantum Systems
- Xanadu to Report Third Quarter 2026 Financial Results on November 11th, 2026
- Xanadu Secures Up to USD $10 Million in Additional DARPA Support to Accelerate Quantum R&D Roadmap
- SEC Form 424B3 filed by Xanadu Quantum Technologies Limited
- SEC Form 424B3 filed by Xanadu Quantum Technologies Limited